|
|
 |
| Epigenomics AG reviews all options for the commercialization of cancer screening test products after end of collaboration with Roche Diagnostics |
Friday, 15.12.2006 |
|
-
Roche Diagnostics notified Epigenomics about the termination of the joint collaboration on screening tests for early detection of cancer and returns licensed marker Septin 9
-
Epigenomics announces positive clinical data for colorectal and prostate cancer screening test programs
-
New data show the development and commercialization potential of molecular diagnostic test products
Ad hoc, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics AG: PITX2 Prostate Cancer Molecular Classification Test Successfully Transferred to Affymetrix Diagnostic Platform |
Tuesday, 12.12.2006 |
|
- Concordance study demonstrated excellent agreement between Epigenomics’ chosen commercial diagnostic test platform and prototype research assays.
- Based on a prior FDA Early Collaboration Meeting, Epigenomics believes a “de novo 510(k)” will be a least burdensome approach for regulatory clearance.
- Product development is on track with pivotal clinical studies scheduled to commence in 2007.
Press release, Berlin, Germany and Seattle, WA, USA
|
|
| Epigenomics AG Reports Third Quarter 2006 Results |
Thursday, 02.11.2006 |
|
- Business Fundamentals and Product Development well on Track
- Search for CEO under way – completion expected by year-end
- Cash position in line with guidance; revenue and earnings behind expectations
Press release, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics AG: Focus on late stage product development |
Thursday, 26.10.2006 |
|
· Berlin operations streamlined – workforce reduced by 34 positions
· Business strategy unchanged – focus on key value drivers
Ad hoc, Berlin, Germany and Seattle, WA, USA
|
|
| Epigenomics AG Successfully Completes First Step towards Lung Cancer Screening Test Development |
Thursday, 05.10.2006 |
|
Many novel candidate DNA methylation biomarkers discovered - Candidate biomarkers broadly applicable to major subtypes of lung cancer - Clinical validation studies in blood to begin in 2007
Press release, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics announces change in the Executive Board |
Friday, 18.08.2006 |
|
Ad hoc, Berlin, Germany and Seattle, WA, USA
|
|
| Epigenomics AG Enters into Agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C |
Monday, 07.08.2006 |
|
| Press release, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics AG Reports Second Quarter 2006 Financial Results |
Thursday, 03.08.2006 |
|
Earnings and cash position within expectations - Qiagen EpiTect research product launched – Strategic Affymetrix diagnostics platform deal signed
Press release, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics AG Decides Capital Increase - Affymetrix Signs For New Shares |
Friday, 21.07.2006 |
|
| Ad hoc, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics AG Presents New Clinical Data on Colorectal Cancer Screening Markers |
Wednesday, 05.07.2006 |
|
| Press release, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics AG and Affymetrix announce Strategic Diagnostics Platform Agreement |
Tuesday, 27.06.2006 |
|
Ad hoc, BERLIN, Germany, SEATTLE, WA, USA and SANTA CLARA, CA, USA |
|
| Epigenomics AG and Wellcome Trust Sanger Institute Release Epigenetic Data on the first 3 Chromosomes |
Monday, 26.06.2006 |
|
| Press release, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics AG Announces Research Collaboration with Stanford University |
Thursday, 08.06.2006 |
|
| Press release, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics AG Announces Continuation of Pharmaceutical Biomarker Research Collaboration with AstraZeneca in the Field of Oncology |
Tuesday, 16.05.2006 |
|
| Press release, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics Receives Award for Best Oral Presentation at MipTec 2006 |
Friday, 12.05.2006 |
|
| Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics AG Reports First Quarter 2006 Results |
Wednesday, 03.05.2006 |
|
| Press release, Berlin, Germany and Seattle, WA, USA |
|
| Qiagen Eliminates Key Bottleneck in Epigenetic Research |
Tuesday, 25.04.2006 |
|
First Product to Streamline the Preanalytical Process for DNA Methylation Analysis in Clinical and Molecular Diagnostics Research Launched
|
|
| Clinical Study Proves Prognostic Power of Epigenomics' Biomarker in Prostate Cancer |
Wednesday, 05.04.2006 |
|
| Press release, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics Presents Data Confirming Screening for Methylated DNA in Blood as Key to Early Colorectal Cancer Detection |
Monday, 03.04.2006 |
|
| Press release, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics AG Reports Financial Results for Fiscal Year 2005 |
Friday, 24.03.2006 |
|
| Press release, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics AG Reports Extension of Blood Screening Product Collaboration |
Wednesday, 22.03.2006 |
|
| Ad hoc, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics AG to Host Press Conference and Analyst Meeting for 2005 Annual Results |
Friday, 17.03.2006 |
|
| Press release, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics Confirms Lead Marker for Prediction of Breast Cancer Relapse |
Friday, 10.03.2006 |
|
| Ad hoc, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics AG Pursuing Development of Tamoxifen Response Test |
Monday, 30.01.2006 |
|
| Ad hoc, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics Successfully Completes Biomarker Validation Study for Prostate Cancer Classification Test |
Wednesday, 04.01.2006 |
|
Ad hoc, Berlin, Germany and Seattle, WA, USA |
|
| Epigenomics AG adds Regulatory Affairs and Marketing Expertise to Senior Management |
Wednesday, 04.01.2006 |
|
| Press release, Berlin, Germany and Seattle, WA, USA |
|
top of the page
|
